First Zika, now Delta Plus indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Third wave: State ropes in edu dept for kids’ awareness
ByVicky PathareVicky Pathare / Updated: Jul 11, 2021, 06:00 IST
Experts create COVID-19 guidelines for schools; teachers to ensure implementation
Children more often than not listen to their teachers and considering this, the state government has roped in the education department to create awareness among kids, ahead of the third COVID-19 wave.
According to health experts, the upcoming wave of the pandemic is expected to afflict children the most.
Anticipating this, health experts and
Paediatric Task Force members will draft guidelines for schools. These guidelines will be prepared with contributions from experts from the education department, school administration, teachers and other field experts, said
3,600 COVID samples in Maharashtra go for genome sequencing
3,600 COVID samples in Maharashtra go for genome sequencing
ByVicky PathareVicky Pathare / Updated: Jul 1, 2021, 06:00 IST
Pune’s BJMC houses the central coordinating lab for sequencing in Maharashtra; PIC FOR REPRESENTATION
CSIR-IGIB in New Delhi to share results in July; the activity will help medical experts to stay ahead of potentially fatal new variants
As worries over new strains continue to sound out in the state, as many as 3,600 samples of COVID-positive patients from
Maharashtra have now been sent to the national Council of Scientific and Industrial Research – Institute of Genomics and Integrative Biology (CSIR-IGIB) in New Delhi for
The city-based PNB Vesper Life Sciences has successfully completed phase 2 clinical trials of PNB-001 (GPP-Baladol), its proprietary drug to treat the coronavirus infection and said it will soon move the government for deploying the drug for emergency use. The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support. The company on Monday said the clinical trial was initiated in November at BJ Government Medical College and Sassoon General Hospital in Pune, and Victoria Medical College and Research Institute in Bengaluru on 40 patients.
Kochi-based pharma firm s new drug shows promising results against COVID-19
The trial was conducted on 40 patients since November at BJ Government Medical College and Sassoon General Hospital Pune and Victoria Medical College and Research Institute, Bangalore
PB Jayakumar | February 22, 2021 | Updated 15:08 IST
GPP-Baladol, a novel chemical entity (NCE) being developed by pharmaceutical research firm PNB Vesper Life Science for treating Covid-19 patients, claims to have shown promising results in the Phase 2b clinical trials. The pharma firm will soon seek Indian drug regulators approval for emergency use in the country.
The trial was conducted on 40 patients since November at BJ Government Medical College and Sassoon General Hospital Pune and Victoria Medical College and Research Institute, Bangalore. The clinical trial report will be submitted to the DCGI today seeking for an Emergency Use Authorisation to treat hospitalised patients in the country in a clinical trial